IPO Boutique Research, Color & More Information for Subscribers
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: YRC Worldwide-BLOCK Symbol: YRCW Price: Last trade $10.98 Trade Date: 1/28 Shares: 1.1 million shares Underwriter(s) Barclays Rating=Subscription Needed
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Baxalta Incorporated Symbol: BXLT Price: Last trade $41.05 Trade Date: 1/28 Shares: 35.3 million Underwriter(s) J.P. Morgan Rating=Subscription Needed Company: Molson[…]
The biotech barometer may be here. Editas Medicine (Nasdaq: EDIT), a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes, updated terms for its IPO and has scheduled a February 3rd trade date. The interest in this deal is currently very large for a few reasons. For[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Agile Therapeutics Symbol: AGRX Price: Last trade $7.06 Trade Date: 1/22 Shares: 4.25 million Underwriter(s) William Blair, RBC Capital Markets Co[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Treehouse Foods Symbol: THS Price: Last trade $71.61 Trade Date: 1/21 Shares: 10.5 million Underwriter(s) BofA Merrill Lynch, J.P. Morgan, Wells[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Sovran Self Storage Symbol: SSS Price: Last trade $109.79 Trade Date: 1/20 Shares: 2.3 million Underwriter(s) Wells Fargo Securities, Jefferies Rating=Subscription[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: EPR Properties Symbol: EPR Price: Last trade $57.75 Trade Date: 1/15 Shares: 2.25 million Underwriter(s) J.P. Morgan, KeyBanc Capital Markets Rating=Subscription[…]
Prior to last year’s J.P. Morgan Healthcare Conference, Moderna Therapeutics made waves with the largest biotech private funding round ever–a $446m round in December 2014. And now, the news is spreading to the masses. Moderna Therapeutics, a company that focuses on using messenger RNA, or mRNA, to spur the production of human proteins within patient[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Equity One-BLOCK Symbol: EQY Price: Last trade $26.32 Trade Date: 1/13 Shares: 11.36 million Underwriter(s) UBS Investment Bank Rating=Subscription Needed
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Education Realty Trust Symbol: EDR Price: Last trade $37.20 Trade Date: 1/12 Shares: 5.5 million Underwriter(s) BofA Merrill Lynch, KeyBanc Capital[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Ardelyx, Inc. Symbol: ARDX Price: Last trade $14.96 Trade Date: 1/8 Shares: 5 million Underwriter(s) Citi, Leerink Partners, Wedbush PacGrow Co[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Adamas Pharmaceuticals, Inc. Symbol: ADMS Price: Last trade $27.91 Trade Date: 1/7 Shares: 2.5 million Underwriter(s) Cowen & Co., Piper Jaffray[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Akebia Therapeutics, Inc. Symbol: AKBA Price: Last trade $12.56 Trade Date: 1/7 Shares: 6 million Underwriter(s) Morgan Stanley, UBS Investment Bank,[…]
2015 US IPO Market Analysis and Review Following two years of strong markets, with 213 deals pricing in 2013 for $54.9 billion and 261 deals pricing in 2014 for $85.3 billion, 2015 experienced a steep decline. Only 153 deals priced for $30.0 billion in proceeds in 2015, the lowest total since 2009. It should be[…]